LLR Adult Asthma Guideline (≥18 years) AIR and MART FAQ(490 KB)
Date added: 6th Nov 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| MEMANTINE | Yellow | Alzheimer's disease |
In line with NICE NG 97
|
| MEMANTINE (NEW) | Green | Alzheimer's Disease |
GPs may initiate memantine in patients already established on treatment in memory services and stabilised on a cholinesterase inhibitor In line with the NICE NG 97 & The Dementia Prescribing Guide |
| PORCINE INSULIN (Hypurin® Porcine 30/70 Mix) (UPDATED) | Green | Diabetes Mellitus |
Not recommended for new initiations, stable patients can continue. VIAL presentations ONLY of Hypurin® Porcine 30/70 Mix are being discontinued. Cartridge presentations remain available. The 3ml penfills (cartridges) can be used in the new Mypen2 reusable insulin pen device. The Mypen 2 will be available from week commencing 20/10/2025. Extracting insulin from pre-filled pens and cartridges is considered a NEVER event and should not occur in clinical practice. |
| PORCINE INSULIN (Hypurin® Porcine Isophane) (UPDATED) | Green | Diabetes Mellitus |
Not recommended for new initiations, stable patients can continue. VIAL presentations ONLY of Hypurin® Porcine Isophane are being discontinued. Cartridge presentations remain available. The 3ml penfills (cartridges) can be used in the new Mypen2 reusable insulin pen device. The Mypen 2 will be available from week commencing 20/10/2025. Extracting insulin from pre-filled pens and cartridges is considered a NEVER event and should not occur in clinical practice. |
| PORCINE INSULIN (Hypurin® Porcine Neutral) (UPDATED) | Green | Diabetes Mellitus |
Not recommended for new initiations, stable patients can continue. VIAL presentations ONLY of Hypurin® Porcine Neutral are being discontinued. Cartridge presentations remain available. The 3ml penfills (cartridges) can be used in the new Mypen2 reusable insulin pen device. The Mypen 2 will be available from week commencing 20/10/2025. Extracting insulin from pre-filled pens and cartridges is considered a NEVER event and should not occur in clinical practice. |
| Relugolix (UPDATED) | Do not prescribe | For treating hormone sensitive prostate cancer |
Relugolix has been temporarily removed from the LLR formulary, pending development of local clinical pathway and funding model to support safe, equitable and sustainable implementation across LLR health system. Please see LLR APC Position Statement: Relugolix (Orgovyx®) for Hormone-Sensitive Prostate Cancer |
| ZURANOLONE (Zurzuvae®) (NEW) | Do not prescribe |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR APC Meeting Minutes October 2025(314 KB) - LMSG/LLR APC minutes
Date added: 6th Nov 2025
LLR APC Position Statement: Relugolix (Orgovyx®) for Hormone-Sensitive Prostate Cancer(170 KB)
Date added: 5th Nov 2025
LLR APC Meeting Minutes September 2025(364 KB) - LMSG/LLR APC minutes
Date added: 13th Oct 2025
Delayed Prescribing Supporting Resource: Prescribing instructions for SystmOne and Emis Users(922 KB)
Date added: 9th Oct 2025
Delayed Prescribing Supporting Resource: Video Guide for Emis Users
Date added: 9th Oct 2025
Delayed Prescribing Supporting Resource: Video Guide for SystmOne Users
Date added: 9th Oct 2025
Implementing Back-up (delayed) Antibiotic Prescribing(247 KB)
Date added: 9th Oct 2025
Haloperidol 0.5mg Tablets Review Process(569 KB)
Date added: 8th Oct 2025
Neuroleptic Malignant Syndrome Guidelines(253 KB) - Guidelines
Date added: 10th Oct 2022
Edoxaban Patient Information Leaflet(210 KB) - Guidelines
Date added: 2nd Jul 2018
Rivaroxaban Patient Information Leaflet(219 KB) - Guidelines
Date added: 2nd Jul 2018
Dabigatran Patient Information Leaflet(212 KB) - Guidelines
Date added: 2nd Jul 2018
Apixaban Patient Information Leaflet(211 KB) - Guidelines
Date added: 2nd Jul 2018
LLR APC Members(78 KB) - Uncategorised
Date added: 28th May 2015
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more